MedTrace Logo

Intravenous (IV) Lidocaine for Opioid-refractory Pain

NCT00321347 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-22

No results posted yet for this study

Summary

Opioid medicines, like morphine, are the main treatment for severe cancer pain. Unfortunately, some patients suffer severe pain despite high doses of opioids. We hypothesize that intravenous lidocaine can quickly and effectively treat this kind of opioid-refractory pain.

Conditions

Interventions

DRUG

Lidocaine

Sponsors & Collaborators

  • San Diego Hospice & Palliative Care

    lead OTHER

Principal Investigators

  • Jay R Thomas, MD PhD · San Diego Hospice & Palliative Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00321347 on ClinicalTrials.gov